Fed Governor Cook sues Trump over firing attempt
In a recent series of transactions, Scott Gottlieb, a director at Tempus AI , Inc. (NASDAQ:TEM), sold a total of 27,838 shares of the company’s Class A Common Stock. These sales, conducted on March 17, 2025, amounted to approximately $1.36 million, with prices per share ranging from $46.59 to $50.45. The stock, currently trading at $48.03, has shown mixed performance with a 42% gain year-to-date despite recent volatility. According to InvestingPro analysis, analysts have set price targets ranging from $55 to $74.
The transactions were part of a Rule 10b5-1 trading plan adopted by Gottlieb on August 27, 2024. This plan allows insiders of publicly traded corporations to set up a predetermined plan to sell stocks, helping to avoid concerns about insider trading. The sales were made in part to cover tax obligations related to the vesting and settlement of restricted stock units. The company maintains a "FAIR" overall financial health score according to InvestingPro metrics.
Following these transactions, Gottlieb holds 60,676 shares of Tempus AI. The sales were executed in multiple transactions at various prices, with the company providing full details upon request. With a market capitalization of $7.9 billion, Tempus AI currently appears overvalued based on InvestingPro’s Fair Value analysis. Discover comprehensive insights and 7 additional ProTips for TEM through the detailed Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Tempus AI Inc. reported its fourth-quarter earnings for 2024, showing a significant revenue increase of 35.8% year-over-year, reaching $700 million. Despite this growth, the company posted a negative earnings per share of -0.18. Tempus AI has also raised its 2025 revenue guidance to approximately $1.24 billion, which includes contributions from the recent acquisition of Ambry Genetics. This acquisition is expected to enhance Tempus’s capabilities in AI-driven healthcare solutions. In terms of analyst actions, JPMorgan downgraded Tempus AI from Overweight to Neutral, although it raised the price target to $55, citing a fully valued stock following significant share price gains. Meanwhile, Stifel maintained its Hold rating with a $65 price target, reflecting a view that Tempus AI’s market valuation is in line with industry standards. Additionally, Tempus AI announced the acquisition of Deep 6 AI, aiming to improve its clinical trial matching capabilities through AI technology. These developments highlight Tempus AI’s strategic direction and focus on expanding its role in the healthcare technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.